The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

Mahady, Suzanne E.; Webster, Angela C; Walker, Sarah; Sanyal, Arun J.; George, Jacob

doi:10.1016/j.jhep.2011.03.016

Cited by 152 publications

(113 citation statements)

References 46 publications

(92 reference statements)

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…They found that 96-week pioglitazone treatment induced improvement in serum biochemical indices and hepatic pathologic changes. In addition, there are two meta-analyses on thiazolidinediones [71,72]. Both reports showed the efficacy of pioglitazone against hepatic fibrosis.…”

Section: Pharmacologic Interventionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

Section: Pharmacologic Interventionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Thiazolidinediones [peroxisome proliferator-activated receptor (PPAR)-γ agonists] such as pioglitazone and rosiglitazone are insulin sensitizers and were found to be effective to reduce fibrosis in two metaanalyses; [121,122] but the finding was not confirmed when more recent and bigger studies were included in the analysis.…”

Section: [119120]mentioning

confidence: 99%

Advances in the diagnosis and treatment of liver fibrosis

Cheng¹,

Wong²

2017

View full text Add to dashboard Cite

“…In randomized controlled trials, however, ursodeoxycholic acid was unconvincing as it was ineffective as monotherapy at the usual dose [25] . Thiazolidinediones, which function as PPARγ agonists, did show positive effects in patients with NASH in randomized controlled trials, but unfortunately, they result in significant weight gain [26] .…”

Section: Antioxidantsmentioning

confidence: 99%

Treatment of Non-Alcoholic Fatty Liver Disease

Scherer

Dufour²

2016

Dig Dis

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions from steatosis to cirrhosis and hepatocellular carcinoma. Steatosis is a benign reversible condition, which does not need treatment. Cirrhosis and hepatocellular carcinoma are the end stages of any chronic liver disease and do not have etiology-specific treatments. In this chapter, we will review treatment options for non-alcoholic steatohepatitis, which is the progressive form of NAFLD. Basically there are 2 strategies, the first of which is to address lifestyle and the second to use medication. The first approach is the most physiologic, the least expensive, but is also the most difficult to implement. The second approach, which should help patients who failed the first approach, is at the advanced clinical research stage.

show abstract

The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

Cited by 152 publications

References 46 publications

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Advances in the diagnosis and treatment of liver fibrosis

Treatment of Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About